How Roche Diagnostics is transforming Alzheimer’s diagnosis with innovative blood-based biomarkers
1 Oct 2025
Discover how Roche Diagnostics is transforming the diagnosis of Alzheimer’s disease with innovative blood-based biomarkers. In this interview, Cristiano Tunesi, the Neurology International Business Leader, discusses the Elecsys® pTau tests and their role in early detection, including the Elecsys pTau181 blood test to rule out Alzheimer’s disease, which recently received CE approval, and the Elecsys pTau217, which can distinguish Alzheimer’s disease from other neurodegenerative disorders. He also addresses the challenges of integrating these tests into primary care and shares insights on Roche’s future innovations in neurology, which encompass Alzheimer’s, Parkinson’s disease, multiple sclerosis, and more.
About the company
Roche Diagnostics Schweiz AG
We believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about transforming patients’ lives. We are courageous in both decision and action. And we believe that good business means a better world. That is why we come to work each day. We commit ourselves to scientific rigour, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow. We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world. We are Roche.